Alterity Therapeutics (ATHE) Payables (2009 - 2026)

Alterity Therapeutics has reported Payables for 18 years, with the latest figure at $1.4 million in Q2 2026.

• On a quarterly basis, Payables fell 12.86% year-over-year to $1.4 million in Q2 2026; TTM through Jun 2026 was $1.4 million, a 12.86% decrease from a year earlier, with the FY2026 full-year figure at $1.4 million, up 390.28% from the prior year.
• Payables was $1.4 million for Q2 2026 at Alterity Therapeutics, up from $1.0 million in the prior quarter.
• The five-year high for Payables was $3.6 million in Q2 2022, with the low at -$1.6 million in Q2 2023.
• Average Payables over 5 years is $1.4 million, with a median of $1.4 million recorded in 2026.
• The sharpest annual moves came in 2023 and 2025: Payables slumped 144.28% in 2023, then surged 424.81% in 2025.
• Over 5 years, Payables stood at $2.9 million in 2022, then fell by 19.05% to $2.4 million in 2023, then sank by 43.27% to $1.3 million in 2024, then declined by 21.85% to $1.0 million in 2025, then soared by 37.13% to $1.4 million in 2026.
• The last three Payables figures came in at $1.4 million (Q2 2026), $1.0 million (Q4 2025), and $1.6 million (Q2 2025), per Business Quant data.